Rasna Therapeutics Inc

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

53.15%

Rev. gr., 5y

Revenues

Net income

-4m

L+546.72%

CFO

-9k

L-97.28%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Actavia Life Sciences, Inc. operates as a biotechnology enterprise specializing in the development of therapeutic solutions aimed at treating various forms of leukemia and lymphoma. Additionally, the company is engaged in formulating small molecule drug candidates, with a particular emphasis on addressing acute myeloid leukemia. Established in 2013, its corporate headquarters are situated in New York, NY.

Key people

Tiziano Lazzaretti

Chief Financial Officer · since 2016

Alessandro Padova

Chairman of the Board · since 2016

John Brancaccio

Independent Director · since 2016

URL

https://www.rasna.com/

IPO date

Mar 28, 2014

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑09	2022‑09	2021‑09	2020‑09	2019‑09	2018‑09	2017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT